Heart failure & cardiomyopathiesResearch article
Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure
- Modelling study
- sensitivity analysis
Authors' conclusion
Improvement in use of GDMT could result in substantial mortality benefits on a global scale.
Study context
- Population
- People with heart failure with reduced ejection fraction (HFrEF) worldwideestimated HFrEF population
- Participants
- 28.89 million people
- Comparison
- Optimal implementation of quadruple guideline-directed medical therapy (GDMT) vs current treatment rates
- Outcome
- All-cause mortality
- Follow-up
- 12 months
Main finding
As reported in the abstract
Deaths potentially prevented by optimal quadruple GDMT
Deaths potentially prevented
1 188 277 (95% CI 767 933-1 914 561)
Further findings
Eligible but not receiving each GDMT class
- β-blockers
- 8 235 063 (95% CI 6 296 020-10 762 972)
- ARNI
- 20 387 000 (95% CI 15 867 004-26 184 996)
- MRA
- 12 223 700 (95% CI 9 376 895-15 924 973)
- SGLT2 inhibitors
- 21 229 170 (95% CI 16 537 400-27 242 688)
Regional distribution of deaths averted
- Large proportion projected in Southeast Asia, Eastern Mediterranean and Africa, and Western Pacific regions
Original publication
Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure. JAMA Cardiol. Published 1 December 2024. doi:10.1001/jamacardio.2024.3023
Summarised from the published abstract; every number is checked against it